Paul L Bartel

Author:

Paul L. Bartel

ISBN #:

0195109384

US Patent:

6337192, Jan 8, 2002

Filed:

Jan 19, 1999

Appl. No.:

09/233086

Inventors:

Paul L. Bartel - Salt Lake City UT
Sean V. Tavtigian - Salt Lake City UT

Assignee:

Myraid Genetics, Inc. - Salt Lake City UT

International Classification:

C12N 1500

US Classification:

435 691, 435325, 4353201, 536 231

Abstract:

The present invention is directed to the MMSC1 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MMAC1 gene.

US Patent:

6653102, Nov 25, 2003

Filed:

Oct 11, 2001

Appl. No.:

09/973963

Inventors:

Jean-Marc Roch - Salt Lake City UT
Paul L. Bartel - Salt Lake City UT
Karen Heichman - Salt Lake City UT
Kimberly Mauck - Sandy UT
Max Dufford - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12N 1500

US Classification:

435 691, 4353201, 435325, 4352523, 43525411, 4352542, 435183, 536 235

Abstract:

The present invention relates to the discovery of proteinâprotein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimers disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

US Patent:

6831154, Dec 14, 2004

Filed:

May 14, 2002

Appl. No.:

10/146710

Inventors:

Paul Bartel - Salt Lake City UT

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C07K 1400

US Classification:

530350

Abstract:

Protein complexes are provided comprising MAP17 and SCAMP2. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with MAP17 and SCAMP2. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

US Patent:

7067312, Jun 27, 2006

Filed:

Sep 19, 2002

Appl. No.:

10/247146

Inventors:

Paul Bartel - Salt Lake City UT, US
Kimberly Ann Mauck - Sandy UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12N 5/00
C12P 21/06
C07H 21/02

US Classification:

435325, 435 691, 530300, 536 231

Abstract:

Novel PN7718 protein and nucleic acids encoding PN7718 are provided. PN7718-containing protein complexes formed by PN7718 and a PN7718-interacting protein (e. g. , cyclophilin C) are also provided. Cyclophilin C and PN7718 may be involved in common biological processes such as intracellular calcium signaling, beta-amyloid formation, T-cell receptor and IgE receptor signaling pathways, and protein folding and degradation. Thus, the protein complexes as well as PN7718 can be used in screening assays to select modulators of PN7718 and the protein complexes formed by PN7718 and cyclophilin C. The identified modulators can be useful in modulating the functions and activities of PN7718 and protein complexes containing PN7718, and in treating and preventing autoimmune diseases, neurological diseases and cardiovascular disorders.

US Patent:

20020040484, Apr 4, 2002

Filed:

Sep 10, 2001

Appl. No.:

09/948904

Inventors:

Jean-Marc Roch - Salt Lake City UT, US
Paul Bartel - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

A01K067/00
A61K038/17

US Classification:

800/008000, 514/012000

Abstract:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

US Patent:

20020045201, Apr 18, 2002

Filed:

Oct 5, 2001

Appl. No.:

09/970898

Inventors:

Jean-Marc Roch - Salt Lake City UT, US
Paul Bartel - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

G01N033/53
G01N033/537
G01N033/543

US Classification:

435/007920

Abstract:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

US Patent:

20020048769, Apr 25, 2002

Filed:

Oct 5, 2001

Appl. No.:

09/970814

Inventors:

Jean-Marc Roch - Salt Lake City UT, US
Paul Bartel - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

C12Q001/68
G01N033/53
C12N009/16
C07K016/42

US Classification:

435/006000, 435/007100, 435/196000, 530/388100

Abstract:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

US Patent:

20020054876, May 9, 2002

Filed:

Oct 9, 2001

Appl. No.:

09/971675

Inventors:

Jean-Marc Roch - Salt Lake City UT, US
Paul Bartel - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

A61K039/395

US Classification:

424/146100

Abstract:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD) Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.